A Randomized Comparison of Second-Line Lopinavir/ Ritonavir Monotherapy versus Tenofovir/Lamivudine/ Lopinavir/Ritonavir in Patients Failing Nnrti Regimens: The HIV Star Study

201250 citationsJournal Articlebronze Open Access

Authors

Torsak Bunupuradah · HIV Netherlands Australia Thailand Research Collaboration

Ploenchan Chetchotisakd · Khon Kaen University

Jintanat Ananworanich · HIV Netherlands Australia Thailand Research Collaboration

Warangkana Munsakul · Vajira Hospital

Supunnee Jirajariyavej

Pacharee Kantipong · ChiangRai Prachanukroh Hospital

Wisit Prasithsirikul · Bamrasnaradura Infectious Diseases Institute

Abstract

In PI-naive patients failing NNRTI-based first-line HAART, mono-LPV/r had a significantly lower proportion of patients with HIV RNA<50 copies/ml compared to the TDF/3TC/LPV/r treatment. Thus, mono-LPV/r should not be recommended as a second-line option.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Antiviral Therapy

Volume 17, Issue 7, pp. 1351-1361

DOI: 10.3851/imp2443

Field-Weighted Citation Impact: 5.01